Lung Cancer - Non Small Cell
Conditions
Keywords
NSCLC, radiomics, PFS, fibrosis
Brief summary
Patients with suspected Lung cancer who underwent contrast-enhanced CT and pathological examinations at Center 1 between January 2011 and January 2020 and Center 2 between September 2017 and Januray 2020 were eligible for inclusion in this study.The Clinical data, preoperative clinical information, laboratory results, CT images and pathological sections were collected. The investigators also collected the disease-free survival and overall survival time. On the Deepwise multi-modal research platform, the images were semi-automatically segmented and PyRadiomics was used to extract the radiomic features. Fibrosis quantification was performed on picrosirius red (PSR)-stained tissue sections using color deconvolution and binarized collagen signal analysis in ImageJ software. The investigators developed RaFIST, a radiomics-based stratification tool, to noninvasively quantify intratumoral fibrosis in non-small cell lung cancer (NSCLC) using contrast-enhanced CT imaging. And it was further tested on the held-out external test cohort. Discrimination was assessed by using the C-index and area under the receiver operating characteristic curve (AUC).
Interventions
OTHERCT radiomic analysis
Radiomic features of tumor tissue
OTHERFibrosis assessment
Fibrosis quantification was performed on picrosirius red (PSR)-stained tissue sections using color deconvolution and binarized collagen signal analysis in ImageJ software (v1.5)
Sponsors
Jinling Hospital, China
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Solid pulmonary nodule detected on CECT within 3 weeks pre-resection * No history of previous treatment such as chemotherapy, or radiotherapy
Exclusion criteria
* Unavailable pathological sections * Missing CT images or hard-to-annotate CT images * Undergone anticancer therapy before CT * Loss to follow-up * Concurrent other malignant tumors
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| DFS (Disease-free survival) | Record from the date of surgery to the date of recurrence or death from any cause, whichever comes first, and assess up to a maximum of 5 years. | DFS was defined as the duration from the date of primary surgery to the first occurrence of recurrence or death from any cause. |
Secondary
| Measure | Time frame |
|---|---|
| OS (overall survival） | Record from the date of surgery to the date of death from any cause，whichever comes first, and assess up to a maximum of 5 years. |
Countries
China
Outcome results
None listed